“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Mediceo Aiming for 20% Market Share in Hokkaido within 3 Years: President Watanabe
October 7, 2011
-
BUSINESS Aiming for 6% Yearly Growth by Rivaroxaban Launching: Bayer AG
October 6, 2011
-
REGULATORY Number of Pharmacies Qualifying for Premiums for GE Drug Dispensing Systems Down in 2010
October 6, 2011
-
BUSINESS Takeda President Hasegawa Says Innovation Will Take Place in Developing Countries
October 5, 2011
-
BUSINESS Ono and Germany’s Merck Enter into License Agreements to Boost Priority Fields
October 5, 2011
-
ORGANIZATION Leading Biotech Clusters in Osaka, Munich Sign Partnership Agreement
October 5, 2011
-
REGULATORY FPMAJ States Difficulty in Identifying Anticancer Drugs in Terms of Adverse Reactions
October 4, 2011
-
BUSINESS Mochida’s New 3-Year Business Plan Aims for Sales of ¥100 Bil. in FY2013
October 4, 2011
-
BUSINESS Takeda Completes Acquisition of Nycomed, Global Rx Sales Ranking Up to 12th
October 3, 2011
-
ORGANIZATION Takeda “Will Be Able to Get Through” Power Shortages: Mr Hasegawa
October 3, 2011
-
ORGANIZATION “Permanent Introduction of Premium for New Drug Development Premature”: CSIMC Member Adachi
September 30, 2011
-
BUSINESS MS Pharma Forms Strategic Alliance with Korean Company in Biosimilars
September 30, 2011
-
BUSINESS Takeda President Hasegawa Eyes Joint Research with Chinese Companies
September 29, 2011
-
REGULATORY CSIMC’s Committee to Assess Premium for New Drug Development Based on Results of Market Price Survey
September 29, 2011
-
BUSINESS MTPC to Start PIII Trial for Telaprevir in China Early 2012
September 29, 2011
-
ORGANIZATION JPMA Head Says Industry Will Support Infrastructure Development for Innovative Drug Discovery
September 28, 2011
-
BUSINESS Astellas Pharma Debuts on DJSI Asia Pacific Index
September 28, 2011
-
BUSINESS BMS to File for Apixaban for Stroke Prevention in Japan, US, and Europe Before Year-end
September 27, 2011
-
ORGANIZATION Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen
September 26, 2011
-
REGULATORY 6 APIs/10 Products Including EpiPen Added to NHI Price List
September 22, 2011
ページ
Pharma companies have seen Japan’s new “zero” premium coefficient rule extensively applied to medicines with low cost disclosure ratios since its introduction under the drug pricing reform this April. Of new drugs listed in the past two months, all six…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…